Arch <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Files for Chapter 11 Bankruptcy; Court Approves Asset Sale Bidding Procedures and Stalking Horse Bid
Arch Therapeutics, Inc. has initiated bankruptcy proceedings under Chapter 11, filing voluntary petitions alongside its subsidiary, Arch Biosurgery, Inc., in the United States Bankruptcy Court for the District of Massachusetts. The company continues operations as a debtor-in-possession and has accepted a stalking horse bid for the sale of substantially all its assets, with the possibility of higher offers. A hearing to approve the asset sale is scheduled for June 20, 2025. The bankruptcy proceedings may lead to the cancellation of all equity securities without any recovery to shareholders. The court has authorized Arch Therapeutics to secure postpetition financing and use cash collateral, granting liens and superpriority administrative expense status. The company aims to confirm a Chapter 11 plan of liquidation, including a Section 363 sale of its assets free of liens and claims, within seven weeks. Vivex Biologics, Inc. has been designated as the stalking horse bidder, with a credit bid of up to $900,000 in DIP obligations and additional cash commitments.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arch Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-012288), on May 23, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.